Capture of mesothelioma cells with ‘universal’ CTC-chip
Authors:
- 14 December 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (2) , 2635-2640
Abstract
Malignant mesothelioma (MM) is a highly aggressive malignant tumor, predominantly associated with job‑related exposure to asbestos. Development of effective and non‑invasive modalities for diagnosis is an important issue in occupational medicine. Circulating tumor cells (CTCs), which are tumor cells that are shed from primary tumors and circulate in the peripheral blood, may be detected at an earlier stage than malignant tumors, and detection of CTCs may provide a novel insight into the diagnosis of MM. In a previous study evaluating clinical utility of CTCs, detected with a widely used system ‘CellSearch’, the authors indicated a significant however insufficient capability in the diagnosis of MM, suggesting need for a more sensitive system. Accordingly, the authors developed a novel microfluidic system to capture CTCs (CTC‑chip), and demonstrated that the CTC‑chip effectively captured MM cells (ACC‑MESO‑4) spiked in the blood by conjugating an anti‑podoplanin antibody. The results of the present study demonstrated that the CTC‑chip coated with the anti‑podoplanin antibody captured another MM cell (ACC‑MESO‑1). However, the capture efficiencies were lower than those for ACC‑MESO‑4. In addition, an anti‑mesothelin antibody was used to capture CTCs, however the CTC‑chip coated with the anti‑mesothelin antibody failed to effectively capture MM cells, possibly due to low mesothelin expression. Overall, the CTC‑chip may capture specific types of CTCs by conjugating any antibody against an antigen expressed on CTCs, and may be a useful system for the diagnosis of malignant tumors, including MM.Keywords
This publication has 24 references indexed in Scilit:
- A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin AntibodyThe Journal of Immunology, 2013
- Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-AnalysisJournal of Clinical Oncology, 2012
- Markers for the non-invasive diagnosis of mesothelioma: a systematic reviewBritish Journal of Cancer, 2011
- Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesotheliumLaboratory Investigation, 2010
- Circulating tumor cells (CTCs) in lung cancer: current status and future perspectivesLung Cancer: Targets and Therapy, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- Malignant pleural mesothelioma: current concepts in treatmentNature Clinical Practice Oncology, 2007
- Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysisThe Lancet, 2007
- Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patientsCancer Science, 2006